Foghorn Therapeutics annual total assets
2019
2020
2021
2022
2023
2024
2025
Foghorn Therapeutics Total Assets Growth & History (FHTX)
Foghorn Therapeutics's total assets was $198.1M for fiscal 2025.
View full Foghorn Therapeutics company overviewFoghorn Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $198.1M | −$85.9M | −30.24% |
| 2024 | 2024-12-31 | $284.0M | −$1.9M | −0.68% |
| 2023 | 2023-12-31 | $285.9M | −$119.0M | −29.38% |
| 2022 | 2022-12-31 | $404.9M | −$114.9M | −22.10% |
| 2021 | 2021-12-31 | $519.8M | $264.2M | +103.36% |
| 2020 | 2020-12-31 | $255.6M | $233.3M | +1044.01% |
| 2019 | 2019-12-31 | $22.3M | — | — |
Foghorn Therapeutics quarterly total assets
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $203.4M | −$22.8M | −10.10% |
| Q1 2026 | 2026-03-31 | $222.2M | −$36.5M | −14.12% |
| Q4 2025 | 2025-12-31 | $198.1M | −$85.9M | −30.24% |
| Q3 2025 | 2025-09-30 | $205.0M | −$103.4M | −33.53% |
| Q2 2025 | 2025-06-30 | $226.2M | −$102.3M | −31.15% |
| Q1 2025 | 2025-03-31 | $258.7M | $3.7M | +1.45% |
| Q4 2024 | 2024-12-31 | $284.0M | −$1.9M | −0.68% |
| Q3 2024 | 2024-09-30 | $308.4M | −$5.1M | −1.61% |
| Q2 2024 | 2024-06-30 | $328.6M | −$11.0M | −3.24% |
| Q1 2024 | 2024-03-31 | $255.0M | −$117.9M | −31.61% |
| Q4 2023 | 2023-12-31 | $285.9M | −$119.0M | −29.38% |
| Q3 2023 | 2023-09-30 | $313.4M | −$120.5M | −27.77% |
| Q2 2023 | 2023-06-30 | $339.6M | −$117.3M | −25.68% |
| Q1 2023 | 2023-03-31 | $372.9M | −$115.4M | −23.64% |
| Q4 2022 | 2022-12-31 | $404.9M | −$114.9M | −22.10% |
| Q3 2022 | 2022-09-30 | $433.9M | $247.9M | +133.21% |
| Q2 2022 | 2022-06-30 | $456.9M | $248.4M | +119.11% |
| Q1 2022 | 2022-03-31 | $488.3M | $258.4M | +112.41% |
| Q4 2021 | 2021-12-31 | $519.8M | $264.2M | +103.36% |
| Q3 2021 | 2021-09-30 | $186.1M | $43.6M | +30.64% |
| Q2 2021 | 2021-06-30 | $208.5M | — | — |
| Q1 2021 | 2021-03-31 | $229.9M | — | — |
| Q4 2020 | 2020-12-31 | $255.6M | $233.3M | +1044.01% |
| Q3 2020 | 2020-09-30 | $142.4M | — | — |
| Q4 2019 | 2019-12-31 | $22.3M | — | — |
Foghorn Therapeutics total assets trends
Over the last five fiscal years, Foghorn Therapeutics's total assets decreased from $255.6M to $198.1M, a change of −$57.5M. The latest reported quarter, Q2 2026, shows $203.4M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Foghorn Therapeutics source filings ↗